Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

Bone Marrow Transplantation volume 56, pages 992–996 (2021)Cite this article

Subjects

Recent studies investigated the outcomes of patients with relapsed/refractory (R/R) follicular lymphoma (FL) undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT) [1, 2]. Risk factors for progression-free survival (PFS) such as age [1,2,3,4], number of chemotherapy regimens [2], chemosensitivity or response before ASCT [1,2,3,4,5], performance status [2], and extranodal involvement [4] have been reported, but not consistently, across studies. Also, data on head-to-head comparisons according to different donor types are lacking. The aims of the study were to evaluate long-term outcomes, identify prognostic factors for PFS, and provide data comparing MSD, MUD, and haploidentical donors in 194 patients with R/R FL who underwent allo-HSCT.

Patients with R/R grades 1-3b FL who underwent first allo-HSCT from a MSD, MUD, or haploidentical donor from January 2000 to December 2018 reported to GETH were included. Patients with transformed FL, syngeneic donor, cord blood or mismatched unrelated donor, and ex vivo T cell-depleted grafts were excluded. Chi-square test was used to compare categorical variables and the Wilcoxon test for continuous variables. The probability of acute and chronic GVHD, NRM, and relapse was calculated using the method of cumulative incidence [6, 7]. Unadjusted time-to-event analyses were performed using the Kaplan–Meier estimate [8], and, for comparisons, the log-rank tests [9]. A Cox proportional hazards model or the Fine and Gray method for competing events were used for multivariable analysis [6]. Statistical analyses were performed using R and SPSS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: PFS according to the number of independent risk factors (RF).

References

  1. Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†. Ann Oncol. 2016;27:1088–94.

    Article  CAS  Google Scholar 

  2. Sureda A, Zhang M-J, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer Wiley-Blackwell. 2018;124:1733–42.

    CAS  Google Scholar 

  3. Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, et al. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016;51:58–66.

    Article  CAS  Google Scholar 

  4. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, et al. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biol Blood Marrow Transpl. 2015;21:2091–9.

    Article  Google Scholar 

  5. Heinzelmann F, Bethge W, Beelen DW, Engelhard M, Kroger N, Dreger P, et al. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. Bone Marrow Transplant. 2016;51:654–62.

    Article  CAS  Google Scholar 

  6. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

    Article  Google Scholar 

  7. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

    Article  CAS  Google Scholar 

  8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.

    CAS  PubMed  Google Scholar 

  10. Piñana JL, Martino R, Gayoso J, Sureda A, la Serna de J, Diez-Martin JL, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010;95:1176–82.

  11. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang M-J, Carreras J, et al. The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen. Biol Blood Marrow Transpl. 2015;21:1746–53.

    Article  Google Scholar 

  12. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530–6.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Juan Montoro, Pedro Chorão

Authors and Affiliations

  1. Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

    Juan Montoro, Pedro Chorão, Jaime Sanz & José Luis Piñana

  2. Department of Hematology, Hospital Universitario Son Espases, Mallorca, Spain

    Leyre Bento

  3. Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain

    Mónica Cabrero & Dolores Caballero

  4. Department of Hematology, Hospital Universitario Reina Sofía, Córdoba, Spain

    Carmen Martín

  5. Department of Hematology, Hospital de la Santa Creu i San Pau, Barcelona, Spain

    Silvana Novelli & Irene García Cadenas

  6. Bone Marrow Transplant Unit, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain

    Gonzalo Gutiérrez

  7. Department of Hematology, Hospital General Universitario Morales Meseguer, Murcia, Spain

    Oriana López-Godino

  8. Department of Hematology, Hospital Germans Trials i Pujol, Barcelona, Spain

    Christelle Ferrá

  9. Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Mariana Bastos-Oreiro

  10. Department of Hematology, Hospital Clínico, Valencia, Spain

    Ariadna Pérez

  11. Department of Hematology, Institut Català d’Oncologia (ICO) - Hospital Duran i Reynals, Barcelona, Spain

    Rocío Parody & Ana Sureda

  12. Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IBIS/CIBERONC), Universidad de Sevilla, Sevilla, Spain

    José A. Pérez Simón

  13. Department of Hematology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain

    Lucrecia Yañez

  14. Department of Hematology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

    Andrés Sánchez

  15. Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain

    Joud Zanabili

  16. Department of Hematology, Complejo Hospitalario A Coruña, La Coruña, Spain

    Ma Rosario Varela

  17. Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

    Raúl Córdoba

  18. Department of Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain

    Teresa Zudaire

  19. Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain

    Ana Jiménez-Ubieto

Authors
  1. Juan Montoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro Chorão
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leyre Bento
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mónica Cabrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carmen Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Silvana Novelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Irene García Cadenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gonzalo Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Oriana López-Godino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Christelle Ferrá
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mariana Bastos-Oreiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ariadna Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rocío Parody
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. José A. Pérez Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lucrecia Yañez
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Andrés Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Joud Zanabili
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Ma Rosario Varela
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Raúl Córdoba
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Teresa Zudaire
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Ana Jiménez-Ubieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Jaime Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Ana Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Dolores Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. José Luis Piñana
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of GETH and GELTAMO Group

Corresponding author

Correspondence to Juan Montoro.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Montoro, J., Chorão, P., Bento, L. et al. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. Bone Marrow Transplant 56, 992–996 (2021). https://doi.org/10.1038/s41409-020-01161-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-01161-1

Search

Advanced search

Quick links